(CercleFinance.com) – Given its current performance, Virbac indicates that it now expects, for the year which is ending, a growth in its turnover at constant exchange rates and scope of around 4%, and no longer between 2% and 4%.
Likewise, the animal health group is aiming for a ratio of ‘current operating income before depreciation of assets resulting from acquisitions’ to turnover consolidating around 15% at constant exchange rates, and no longer between 13.5 and 14 .5%.
Furthermore, regarding its 2024 financial year, Virbac declares that at this stage it expects organic growth in its turnover of between 4 and 6%, as well as an adjusted EBIT margin of around 15% at constant exchange rates.